Profile

Christopher Y. Thomas, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

168 Ratings
9 Comments
 

Christopher Y. Thomas, M.D.

Associate Professor,


Clinical Interests

Bladder Cancer, Genitourinary Cancer, Genitourinary Oncology, Prostate Cancer

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Education & Training

  • A.B., University of Kansas, 1970
  • M.D., University of Kansas, 1974
  • Residency, Internal Medicine, Cincinnati General Hosp, 1977
  • Fellowship, Hematology And Oncology, University of Cincinnati, 1978
  • Fellowship, Hematology And Oncology, Tufts University School of Med, 1979
  • Fellowship, Molecular Genetics, Tufts University School of Med, 1981

Board Certifications

  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Internal Medicine, Hematology
  • American Board of Internal Medicine, Internal Medicine, Medical Oncology

NPI Number

  • 1942370119
Christopher Y. Thomas, M.D.

Doctor Rating

4.7 out of 5

168 Ratings
9 Comments
 

Christopher Y. Thomas, M.D.

Associate Professor, Hematology & Oncology
Comprehensive Cancer Center
Urology

Contact Information

Academic: 434-243-6356 | Department: 336-716-4464

Recent Publications

Dillon PM, Chakraborty S, Moskaluk CA, Joshi PJ, Thomas CY. Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck. 2016;38(4):620-627.

Dillon PM, Petroni GR, Moskaluk C, Fracasso PM, Douvas MG, Perez JR, Varhegyi N, Zaja-Milatovic S, Thomas CY. A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC) [abstract]. J Clin Oncol. 2015;33(15 Suppl):e17092.

Hollen PJ, Gralla RJ, Jones RA, Thomas CY, Brenin DR, Weiss GR, Schroen AT, Petroni GR. A theory-based decision aid for patients with cancer: results of feasibility and acceptability testing of DecisionKEYS for cancer. Support Care Cancer. 2013;21(3):889-899.

Dillon PM, Moskaluk C, Fracasso PM, Petroni GR, Thomas CY. Phase II study of dovitinib (TK1258) in patients with progressive metastatic adenoid cystic carcinoma [abstract]. J Clin Oncol. 2013;31(15 Suppl):6021.

Glisson BS, Tseng J, Marur S, Shin DM, Murphy BA, Cohen EEW, Thomas CY, Willey R, Cosaert J, William WN, Harun N, Lee JJ, Haddad RI. Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN) [abstract]. J Clin Oncol. 2013;31(15 Suppl):6030.

Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, Wang Z, Zhang Z, Sun J, Sun J, Koty PP, Kader AK, Cramer SD, Bova GS, Zheng SL, Gronberg H, Isaacs WB, Xu J. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer. 2013;119(13):2405-2412.

Thomas CY, Hemal AK. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int. 2013;112(4):425-426.

Rahimi AS, Wilson DD, Saylor DK, Stelow EB, Thomas CY, Reibel JF, Levine PA, Shonka DC, Jameson MJ, Read PW. p16, Cyclin D1, and HIF-1alpha predict outcomes of patients with oropharyngeal squamous cell carcinoma treated with definitive intensity-modulated radiation therapy. Int J Otolaryngol. 2012;2012():685951.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Hematology & Oncology

Clinical Interests

Bladder Cancer, Genitourinary Cancer, Genitourinary Oncology, Prostate Cancer
Christopher Y. Thomas, M.D.

Christopher Y. Thomas, M.D.

Associate Professor, Hematology & Oncology
Comprehensive Cancer Center
Urology

Doctor Rating

4.7 out of 5

Christopher Y. Thomas, M.D.168 Ratings
9 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.7
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.7
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.8
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.8
Time CP spent with patient
4.6
Wait time at clinic
4.0



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

4/8/2016

Very, very pleased to be a patient of *Dr. Thomas.

3/8/2016

Dr. Thomas was very kind and took time to explain things to us and let us ask questions.

2/9/2016

Very timely with help!

1/14/2016

Compassion and caring.

1/7/2016

Good; if they have cancer.

12/19/2015

Dr. Thomas is a wonderful, professional cancer doctor. I would recommend others to him if they needed a cancer doctor.

9/23/2015

The provider provided plenty of time for me. He didn't seem rushed at all

6/28/2015

Very Good

6/21/2015

Very good experience

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.